Drug Overview

Alectinib is an advanced cancer medication known as a “Targeted Therapy” or a “Smart Drug.” Unlike traditional chemotherapy that attacks all fast-growing cells in the body, smart drugs are designed to hunt down and block specific broken parts inside cancer cells. This makes the treatment highly precise and helps spare healthy cells.

Alectinib is specially designed to treat a certain type of lung cancer that has a specific genetic change (mutation) called ALK (Anaplastic Lymphoma Kinase). It is considered a major breakthrough in lung cancer care because it can effectively reach the brain, where lung cancer often spreads.

Generic Name: Alectinib
US Brand Names: Alecensa
Drug Class: Tyrosine Kinase Inhibitor (TKI) / Targeted Therapy / ALK Inhibitor
Route of Administration: Oral (Capsule)
FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

To understand how alectinib works, we have to look inside the cancer cell at the molecular level.

In some lung cancers, a piece of DNA breaks and attaches to the wrong place. This creates a mutant protein called ALK. You can think of the ALK protein as a broken cell antenna that is permanently stuck in the “on” position. It constantly sends powerful signals down pathways inside the cell (known to scientists as the STAT3 and AKT signaling pathways). These signals tell the cancer cell to quickly multiply and refuse to die.

Alectinib is a small molecule that acts like a perfectly shaped plug. When a patient takes the medicine, it enters the blood and finds these broken ALK antennas on the cancer cells. It binds directly to the ALK protein and shuts it off. Without this constant “grow” signal, the cancer cells stop dividing and naturally die off.

A critically important feature of alectinib is its ability to cross the blood-brain barrier. The brain has a natural shield that blocks many drugs from entering. Alectinib is specially engineered to slip past this shield, allowing it to hunt down and destroy cancer cells that have hidden in the brain.

FDA Approved Clinical Indications

Alectinib is officially approved by the FDA and major international health agencies for the following specific uses:

Oncological Uses

Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Used as a first-line treatment for patients whose lung cancer has spread to other parts of the body and has the ALK mutation.
Early-Stage ALK-Positive NSCLC (Adjuvant Treatment): Approved recently for patients who have had their lung tumors surgically removed, to prevent the cancer from coming back.

Non-Oncological Uses

None. This medication is strictly used for cancer treatment.

Dosage and Administration Protocols

Alectinib is taken by mouth as a capsule. It is very important to take this medicine with food to ensure the body absorbs it properly.

Patient Age/Type	Route of Administration	Standard Dose	Frequency	Special Instructions
Adults (Standard)	Oral Capsule	600 mg (four 150 mg capsules)	Twice daily (total 1200 mg per day)	Must be taken with food. Swallow capsules whole.

Dose Adjustments

Renal Insufficiency (Kidney Issues): No dose adjustment is needed for mild to moderate kidney problems.
Hepatic Insufficiency (Liver Issues): No dose adjustment is needed for mild liver problems. However, for patients with severe liver impairment (Child-Pugh Class C), the dose is significantly reduced to 450 mg taken twice daily.
Side Effect Adjustments: If severe side effects occur (like liver inflammation or extreme muscle pain), doctors may lower the dose in steps (first to 450 mg twice daily, then to 300 mg twice daily) or pause the medication completely.

Clinical Efficacy and Research Results

Clinical trials between 2020 and 2025 have confirmed that alectinib is one of the most effective targeted therapies available for ALK-positive lung cancer.

Survival Rates in Advanced Cancer: Long-term follow-up from the famous ALEX clinical trial showed that alectinib significantly extended life compared to older ALK drugs. The 5-year overall survival rate for patients on alectinib was an impressive 62.5%. For many patients, the drug stops the tumor from growing for nearly 3 years (about 34.8 months median progression-free survival), which is a historic milestone in metastatic lung cancer.
Brain Metastases: The drug is incredibly effective at preventing the cancer from spreading to the brain and shrinking existing brain tumors.
Early-Stage Cancer Prevention (ALINA Trial): Recent data from the 2023-2024 ALINA trial proved that giving alectinib to patients after surgery reduces the risk of the cancer returning or causing death by over 75% compared to standard chemotherapy.

Safety Profile and Side Effects

Because alectinib specifically targets the ALK protein, it usually avoids the severe side effects of standard chemotherapy, like total hair loss. However, it still has specific side effects that require monitoring.

No Black Box Warning

Currently, there is no FDA Black Box Warning for alectinib.

Common Side Effects (Occur in >10% of patients)

Constipation: A very common issue for patients taking this drug.
Fatigue: Feeling unusually tired or weak.
Edema: Swelling in the face, eyelids, lower legs, or hands.
Myalgia: Muscle aches and joint pain.
Anemia: Low red blood cell counts, which can contribute to tiredness.

Serious Adverse Events (Occur rarely)

Hepatotoxicity: Severe liver damage or inflammation.
Interstitial Lung Disease (ILD) / Pneumonitis: Dangerous, life-threatening inflammation and scarring of the lung tissue.
Bradycardia: A dangerously slow heart rate, causing dizziness or fainting.
Severe Muscle Damage (CPK Elevation): Severe muscle breakdown that can harm the kidneys.

Side Effect Management Strategies

For Constipation: Drink plenty of water, eat a high-fiber diet, and ask your doctor about a daily stool softener or gentle laxative.
For Muscle Pain: Rest when needed. Doctors will check a blood test called CPK to make sure your muscles are safe.
For Edema: Keep your legs elevated when sitting. Your doctor may adjust your dose if the swelling becomes severe.

Research Areas

While alectinib is highly effective, cancer cells can sometimes mutate again to outsmart the drug—a process known as acquired resistance. A major focus of current research is mapping these new mutations (such as the ALK G1202R mutation) to understand why the cancer starts growing again. Scientists are actively testing sequencing strategies, meaning they study exactly which next-generation “smart drug” (like lorlatinib) should be given after alectinib stops working, creating a step-by-step roadmap to turn advanced lung cancer into a manageable, long-term chronic illness.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

Liver Function Tests (LFTs): Blood tests to check liver health before starting, and then every 2 weeks for the first 3 months of treatment.
Heart Rate Check: A baseline check of your heart rate and rhythm (ECG).
CPK Blood Test: To establish a baseline for your muscle enzymes.
Pregnancy Test: For women of childbearing age, as this drug can cause severe harm to an unborn baby.

Precautions During Treatment

Extreme Sun Sensitivity: Alectinib causes severe photosensitivity. Your skin can burn very quickly and painfully if exposed to direct sunlight.

Do’s and Don’ts

DO take your dose at the same times every day, always with a meal or snack containing some fat to help absorption.
DO wear broad-spectrum sunscreen (SPF 50 or higher), long sleeves, and a wide-brimmed hat whenever you go outside. Keep out of the sun as much as possible.
DO tell your doctor immediately if you develop a new, unexplained cough, a fever, or sudden trouble breathing, as this could be a sign of dangerous lung inflammation.
DON’T crush, chew, or open the capsules. They must be swallowed whole.
DON’T become pregnant or father a child while taking this drug. Use highly effective, non-hormonal birth control during treatment and for a period of time after your last dose (usually 1 week for women and 3 months for men, as directed by your doctor).

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease or health condition. Always consult with a qualified healthcare professional or your treating oncologist regarding specific medical concerns, treatment options, or before starting, stopping, or altering any medication regimen. Every patient’s medical situation is unique, and therapies should be customized by a licensed physician.